Previewing Immunovant’s myasthenia gravis study readout — with all its quirky nuance

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

It’s show-me time for batoclimab, the FcRn-targeting antibody treatment from Immunovant and Roivant Sciences. A consequential Phase 3 study readout is coming before the end of the first quarter.

The study results in patients with generalized myasthenia gravis, a debilitating autoimmune disease, will help determine whether batoclimab — or another, more refined antibody also in Immunovant’s pipeline — can compete against Argenx’s Vyvgart, the current top-selling FcRn-targeting treatment.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

US health care workers are at greater risk of suicide than non–health care workers

The risks of death by suicide for six healthcare worker (HCW).

September 28, 2023

MarketingRx roundup: Viatris taps former Moderna exec for commercial chief; Merck debuts PAH effort

New commercial chief at Viatris: Viatris named Corinne Le Goff as its new chief commercial officer on Monday. Le Goff comes from Imunon where she

April 17, 2024

Penumbra says stroke device delayed at least 12 months due to FDA request

Dive Brief: Development of Penumbra’s brain clot removal device has hit another setback, with a regulatory request to change a study endpoint delaying the program

August 4, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.